MetrioPharm AG is a clinical-stage biopharmaceutical development company focused on therapies for acute and chronic inflammatory diseases. MetrioPharm is developing a novel class of self-regulating immunomodulators targeting activated macrophages and inflamed tissues.

Products, services, technology

Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.

Cooperation possibilities

Licensing, strategic partnerships, investments


Europaallee 41, 8004 Zürich, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business